Company Encyclopedia
View More
name
First Trust Multi Cap Value Alpha
FAB.US
News
View More

Delta Air Lines (DAL) Gets a Buy from J.P. Morgan

Jamie Baker from J.P. Morgan has maintained a Buy rating on Delta Air Lines with a price target of $85.00. Baker is a 3-star analyst with an average return of 2.6% and a 50% success rate. The analyst consensus on Delta Air Lines is a Strong Buy with an average price target of $74.06.

Tip Ranks·
US
DAL
-0.37%
Tip Ranks·
US
DAL
-0.37%

CEO Singisetti Files To Sell 3,125 Of Cognizant Technology Solutions Corp [CTSH]

Singisetti Ravi Kumar, CEO of Cognizant Technology Solutions Corp, filed a Form 144 with the SEC on December 4, 2025, to sell 3,125 shares through JP Morgan Securities LLC. The sale must occur within 90 days of filing.

Reuters·
US
CTSH
+1.21%
Reuters·
US
CTSH
+1.21%

Workhorse Group Inc. Stock Underperforms Thursday When Compared To Competitors

Shares of Workhorse Group Inc. (WKHS) fell 5.17% to $0.85 on Thursday, underperforming compared to competitors Tesla Inc. (TSLA) and General Motors Co. (GM). The NASDAQ Composite Index rose 0.22%, while the Dow Jones Industrial Average fell 0.07%. Workhorse's trading volume was 1.1 million, below its 50-day average of 2.3 million. The stock is 94.59% below its 52-week high of $15.75.

Dow Jones·
US
GM
+0.80%
US
WKHS
-5.17%
Dow Jones·
US
GM
+0.80%
US
WKHS
-5.17%

JetBlue Airways Corp. Stock Underperforms Thursday When Compared To Competitors

JetBlue Airways Corp. (JBLU) shares fell 1.27% to $4.65 on Thursday, underperforming compared to some competitors. This decline ended a two-day winning streak and left the stock 44.04% below its 52-week high of $8.31. In contrast, Southwest Airlines rose 0.36%, while Delta Air Lines and United Airlines fell 0.37% and 3.46%, respectively. The NASDAQ Composite Index rose 0.22%, and the Dow Jones Industrial Average fell 0.07% during the mixed trading session.

Dow Jones·
US
UAL
-3.46%
US
JBLU
-1.27%
US
DAL
-0.37%
Dow Jones·
US
UAL
-3.46%
US
JBLU
-1.27%
US
DAL
-0.37%

Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares

Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2

TradingView·
US
BIIB
+0.68%
TradingView·
US
BIIB
+0.68%
Posts
View More

This is important. Intel indicates its foundry breakeven date could be pushed beyond prior exiting '27. This is to account for incremental expenses to support 14A customer. Sees winning an external cu...

  • 0

TSMC will break ground on its first 1.4nm (14 Angstrom) fab in Taichung, Taiwan by end-2025, with mass production in the 2nd half-2028, media report, noting the A14 process will be developed at TSMC’s..................

© 2025 Longbridge｜Disclaimer